Global Cell Banking Outsourcing Market Segmentation, By Type (Master Cell Banking, Viral Cell Banking, and Working Cell Banking), Product (Cord Cell Banking, Adult Stem Cell Banking, Induced Pluripotent Stem Cell Banking, and Embryonic Stem Cell Banking), Cell Type (Stem Cell and Non-Stem Cell), Phase (Bank Storage, Cell Storage Stability Testing, Bank Preparation, and Bank Characterization and Testing) – Industry Trends and Forecast to 2031.
Cell Banking Outsourcing Market Analysis
The cell banking outsourcing market is poised for substantial growth, driven by advancements in biotechnology and the increasing demand for biopharmaceuticals. Developments in the market include the rising adoption of cell and gene therapies, which necessitate efficient banking solutions for stem cells and other biological materials. For instance, companies are now focusing on creating clinical-grade cell banks under stringent Good Manufacturing Practices (GMP) to ensure quality and regulatory compliance. The expansion of pharmaceutical companies into emerging markets, particularly in Asia-Pacific, further fuels demand as these regions present untapped opportunities for large-scale biomanufacturing. Moreover, collaborations between biotechnology firms and contract manufacturing organizations (CMOs) are on the rise, enabling companies to leverage specialized expertise and enhance operational efficiencies. Technological innovations, such as automated cell banking systems and advanced cryopreservation techniques, are also contributing to market growth by improving sample preservation and retrieval processes. As research in regenerative medicine accelerates, the cell banking outsourcing market is set to evolve, supporting the development of novel therapies and improving patient outcomes globally.
Cell Banking Outsourcing Market Size
The global cell banking outsourcing market size was valued at USD 11.98 billion in 2023 and is projected to reach USD 34.42 billion by 2031, with a CAGR of 14.10% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Cell Banking Outsourcing Market Trends
“Rising Adoption of Automation and Digitalization”
The cell banking outsourcing market is experiencing significant growth, influenced by an increasing demand for biopharmaceuticals and advanced therapies. A notable trend in the market is the rising adoption of automation and digitalization in cell banking processes. Such shift enhances efficiency, accuracy, and scalability in handling biological samples, which is crucial for regulatory compliance and quality assurance. For instance, companies such as Lonza are implementing automated systems for cell processing and storage, reducing human error and ensuring consistency in sample quality. Additionally, the trend towards personalized medicine is amplifying the need for robust cell banking solutions, as therapies tailored to individual genetic profiles require precise and well-maintained cellular materials. As the market expands, the integration of automated technologies will not only streamline operations but also facilitate faster development of therapies, positioning cell banking outsourcing as a critical component in the evolving landscape of regenerative medicine and biotechnology.
Report Scope and Cell Banking Outsourcing Market Segmentation
|
Attributes
|
Cell Banking Outsourcing Key Market Insights
|
|
Segments Covered
|
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Key Market Players
|
Merck KGaA (U.S.), Sartorius AG (Germany), BSL Bioservice (Germany), Charles River Laboratories (U.S.), Laboratory Corporation of America Holdings (U.S.), Lonza (Switzerland), SGS Société Générale de Surveillance SA (Switzerland), WuXi AppTec (China), Reliance Life Sciences (India), LifeCell (India), Cryoviva Botech Private Limited (India), Cordlife (Singapore), Texcell (France), GBI (U.S.), TRANSCELL BIOLIFE (India), Cryo-Cell International, Inc. (U.S.), STEMCELL Technologies (U.S.)
|
|
Market Opportunities
|
|
|
Value Added Data Infosets
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Cell Banking Outsourcing Market Definition
Cell banking outsourcing refers to the practice of partnering with external service providers to manage the storage, processing, and distribution of biological samples, such as stem cells and other cell types. This outsourcing allows biopharmaceutical companies, research institutions, and healthcare organizations to focus on their core activities while benefiting from the specialized expertise and advanced technologies of dedicated cell banking facilities. By outsourcing these functions, organizations can ensure compliance with regulatory standards, maintain high-quality sample integrity, and enhance operational efficiency in the development of therapies and treatments
Cell Banking Outsourcing Market Dynamics
Drivers
- Increasing Demand for Monoclonal Antibodies
The increasing demand for monoclonal antibodies is a key driver of the cell banking outsourcing market, as these therapeutic agents are vital for treating diseases such as cancers and autoimmune disorders. According to Umabs-DB, the number of approved and marketed antibody therapies reached 162 in June 2022, highlighting the growing reliance on monoclonal antibodies in clinical practice. Such surge in demand necessitates robust cell banking solutions to ensure the consistent production and quality of these therapies, thus propelling the growth of the cell banking outsourcing market.
- Increasing Adoption of Stem Cell Therapies
The increasing adoption of stem cell therapies is a significant driver of the global cell banking outsourcing market. As advancements in regenerative medicine continue to emerge, stem cell therapies are being recognized for their potential to treat a wide range of conditions, including neurodegenerative diseases, diabetes, and various cancers. Such growing acceptance and utilization of stem cell treatments necessitate robust cell banking solutions to ensure the availability and integrity of these valuable biological materials. For instance, companies like Cryo-Cell International are expanding their services to offer comprehensive stem cell banking solutions, enabling patients and healthcare providers to access high-quality, preserved stem cells for future therapeutic use. This trend not only drives the demand for outsourcing cell banking services but also encourages innovation in storage technologies and processing methods, driving the market for continuous expansion.
Opportunities
- Rising Advancements in Cryopreservation and Cell Bank Preparation Methodologies
The global cell banking outsourcing market is witnessing significant opportunities due to the rising advancements in cryopreservation and cell bank preparation methodologies. These innovations enhance the efficiency and effectiveness of storing biological samples, ensuring their viability for long-term use. For instance, the introduction of new cryoprotectants and automated freezing technologies allows for better preservation of cell integrity, reducing the risk of damage during the freezing and thawing processes. WuXi AppTec, a cell banking solutions company among others, is at the forefront of such advancements, offering that utilize cutting-edge techniques for optimal cell storage. Trending advancements not only facilitates the development of novel treatments but also enhances the scalability of cell-based therapies. As research continues to evolve, the integration of advanced cryopreservation methods will create further opportunities in the cell banking outsourcing market.
- Increasing Investments in R&D Activities
Increasing investments in R&D activities in biotechnology and regenerative medicine is significantly shaping the landscape of the global cell banking outsourcing market. According to the Pharmaceutical Research and Manufacturers Association (PhRMA), biopharmaceutical firms spent about USD 97 billion on R&D in the U.S. in 2017 more than any other industry. Such rise in funding is largely driven by the rising prevalence of chronic diseases and an aging population, which necessitate innovative treatment solutions. For instance, advancements in gene therapy and stem cell research are pivotal in developing personalized medicine approaches, leading to a greater reliance on well-maintained cell banks for effective therapeutic applications. As biotech companies increasingly seek to streamline their operations and enhance their research capabilities, outsourcing cell banking services becomes an attractive solution, enabling them to focus on core R&D efforts while ensuring the integrity and availability of essential biological materials. This trend not only underscores the critical role of cell banking in biopharmaceutical development but also highlights the expanding opportunities within the outsourcing market.
Restraints/Challenges
- Growing Concern Regarding Data Security and Intellectual Property Protection
The growing concern regarding data security and intellectual property protection is a significant challenge in the global cell banking outsourcing market. As companies increasingly outsource their cell banking processes, ensuring the confidentiality and integrity of sensitive biological data is paramount. For instance, when a biotech firm entrusts a third-party provider with its proprietary cell lines, any breach of data security could expose crucial research information, leading to potential financial losses and damage to the firm's reputation. Similarly, in the cell banking sector, a breach could not only jeopardize ongoing research but also lead to loss of trust among clients and partners. Consequently hampering the market growth.
- High Cost Associated with Cell Banking Services
High cost associated with cell banking services presents a significant barrier for smaller biotech firms and research institutions considering outsourcing their cell banking needs. Establishing state-of-the-art facilities and acquiring advanced equipment necessary for effective cell storage and management requires substantial investment, often reaching millions of dollars. For instance, a small biotech start-up developing innovative therapies may find it financially burdensome to invest in a dedicated cell banking facility when their resources are better allocated towards research and development. As a result, many organizations are forced to reconsider their outsourcing strategies, often opting for less costly but potentially less effective alternatives. Consequently, the financial implications of outsourcing can lead to hesitance among smaller players in the market, ultimately impacting innovation and progress in the field of cell-based therapies.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Cell Banking Outsourcing Market Scope
The market is segmented on the basis of type, product, cell type, and phase. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Master Cell Banking
- Viral Cell Banking
- Working Cell Banking
Product
- Cord Cell Banking
- Adult Stem Cell Banking
- Induced Pluripotent Stem Cell Banking
- Embryonic Stem Cell Banking
Cell Type
- Stem Cell
- Cord Cell Banking
- Embryonic Stem Cell Banking
- Adult Stem Cell Banking
- Dental Stem Cell Banking
- IPS Stem Cell Banking
- Non-Stem Cell
Phase
- Bank Storage
- Master Cell Bank Storage
- Working Cell Bank Storage
- Cell Storage Stability Testing
- Cell Storage Stability Testing
- Bank Preparation
- Master Cell Bank Preparation
- Working Cell Bank Preparation
- Bank Characterization and Testing
- Safety Testing
- Viral Cell Banks
- Microbial Cell Banks
- Gene Expression Testing
- Karyology Testing
- Gene Sequencing Testing
- Safety Testing
Cell Banking Outsourcing Market Regional Analysis
The market is analysed and market size insights and trends are provided by country, type, product, cell type, and phase as referenced above.
The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America leads the cell banking outsourcing market, driven by the growing production of vaccines, antibiotics, and therapeutic proteins, along with the presence of numerous biopharmaceutical manufacturers. This dominance is further supported by a wide array of R&D laboratories and the rising prevalence of metabolic disorders, including Parkinson’s, Alzheimer’s, and various cancer types, which are amenable to treatment through gene therapy.
The Asia-Pacific region is projected to experience the highest growth rate during the forecast period from 2024 to 2031. This significant CAGR is attributed to the presence of pharmaceutical companies that are prioritizing the large and relatively untapped populations in Asia.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Cell Banking Outsourcing Market Share
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.
Cell Banking Outsourcing Market Leaders Operating in the Market Are:
- Merck KGaA (U.S.)
- Sartorius AG (Germany)
- BSL Bioservice (Germany)
- Charles River Laboratories (U.S.)
- Laboratory Corporation of America Holdings (U.S.)
- Lonza (Switzerland)
- SGS Société Générale de Surveillance SA (Switzerland)
- WuXi AppTec (China)
- Reliance Life Sciences (India)
- LifeCell (India)
- Cryoviva Botech Private Limited (India)
- Cordlife (Singapore)
- Texcell (France)
- GBI (U.S.)
- TRANSCELL BIOLIFE (India)
- Cryo-Cell International, Inc. (U.S.)
- STEMCELL Technologies (U.S.)
Latest Developments in Cell Banking Outsourcing Market
- In May 2022, Anja Health secured USD4.5 million in seed funding to enhance access to cord blood stem cell banking for all individuals, regardless of race, socioeconomic status, or income. This funding will bolster the company's leadership team, drive strategic growth, and strengthen community engagement.
- In April 2022, Pluristyx, a biotechnology company specializing in advanced therapeutic tools and services, partnered with Accelerated Biosciences, a leader in regenerative medicine known for its proprietary human trophoblast stem cells (hTSCs), to create clinical-grade hESC banks following GMP guidelines.
SKU-